ABBV AbbVie Inc.
AbbVie Inc. (ABBV) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NYSE. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. On this symbol, 8 comparable calls have settled; 75% reached the published sell target. Information only, not financial advice.
Mid-channel
Price is between the two trend lines. Nothing to act on yet.
Read from the last 3 years of history we hold: rising, drifting +21% a year. The target of US$264.48 is below the nearest ceiling (US$274.53), so it does not depend on a breakout. What would overturn this: a close below US$220.40 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 3 years read from
- US$220.40 – US$274.53 Rising channel, +21% a year
- Position in that channel
- 78% 0% at the floor, 100% at the ceiling
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (3 years)
- Lower trend line (3 years)
- Dashed after today: projected 3 months
- Our buy
- Our target
Suggested path
Buy at or below
US$249.51
level as at 15 Oct 2026
Our target
US$264.48
by 10 Nov 2026
Projected move
6.0%
gross, before costs
Price sits between our buy level and our target.
The lines are drawn where this stock has actually turned: 8 touches on the ceiling, 9 on the floor, each fitted to the slope that catches the most of them. Buying one average daily range below its 50-day mean, on heavier volume than usual and while it is still above its 200-day mean, has come up 791 times; measured against the 6% floor — the least a call has to be worth to be worth making, not what it aims at — 73% cleared it, typically in 34 days, with price going about 5% against the entry along the way (63% in the worst case we have on record). Trades that have not reached the target within 3 months are counted as misses, whatever they are worth at the time. The prices above are this stock’s own — its average, its volatility — but the setup is the same one we apply everywhere: derived on eight unrelated tickers, then confirmed on 87 others it was never fitted to. We deliberately do not tune it to each stock: doing so scores worse on history the tuning never saw — 58% against 71% — because it fits the past rather than the future. On this stock the setup has come up 12 times so far, reaching target 75% of the time. The sell price comes from where this stock is projected to be, not from a minimum worth taking: the fitted path reaches 13% above the entry within 90 days, and of the sizes that path supports, 6% is the one that has returned the most per day of money tied up here — measured over the 13 times this entry has come up on this chart, reached 85% of the time, typically in 26 days. Smaller sizes got there sooner but paid less for the weeks they used; larger ones need a break above the projected ceiling, which is not the base case. The date published is whichever is later: that typical time, or the day the projected path itself reaches the price. It is a prediction, so it can be revised: if the run tops out before it gets there, the target is cut to what is actually on the table and you are told the same day. An ordinary pullback is not treated as topping out — those go on to make a new high about 8 times in 10, so they are ridden through. What triggers the revision is price closing below its 50-day trend and staying there, after which the odds of recovery fall to roughly 3 in 10.
On this stock's own history these rules produced 8 settled calls, of which 6 reached target (75%), with an average best move of 6.8%. See the full record.
- Upper line touches
- 8
- Lower line touches
- 9
- Fit confidence
- 48%
- Fitted
- 16 Sept 2026
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael
- Employees
- 57,000
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- 40/100
- Profitability
- 44/100
- Financial health
- 47/100
- Cash generation
- 65/100
Key statistics
- Market cap
- US$463.92B
- Enterprise value
- US$528.18B
- Beta
- 0.28
- Avg volume
- 6.09M
- Revenue per share
- 36.36
- Dividend yield
- 2.60%
- 52-week range
- 190.75-267.47
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- 73.98
- PEG
- 1.08
- Price / sales
- 7.21
- Price / book
- -78.35
- EV / EBITDA
- 24.87
- Gross margin
- 71.48%
- Operating margin
- 29.32%
- Net margin
- 9.81%
- Current ratio
- 0.81
- Quick ratio
- 0.69
- Debt / equity
- -11.93
- Interest cover
- 6.47
Income statement
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | US$61.16B | US$42.96B | US$20.09B | US$4.23B | US$2.37 |
| 2024 | US$56.33B | US$39.43B | US$9.14B | US$4.28B | US$2.39 |
| 2023 | US$54.32B | US$33.90B | US$12.76B | US$4.86B | US$2.72 |
| 2022 | US$58.05B | US$40.64B | US$18.12B | US$11.84B | US$6.63 |
| 2021 | US$56.20B | US$38.75B | US$17.92B | US$11.54B | US$6.45 |
Balance sheet
| Year | Total assets | Total liabilities | Total equity |
|---|---|---|---|
| 2025 | US$133.96B | US$137.19B | -US$3.27B |
| 2024 | US$135.16B | US$131.80B | US$3.33B |
| 2023 | US$134.71B | US$124.31B | US$10.36B |
| 2022 | US$138.81B | US$121.52B | US$17.25B |
| 2021 | US$146.53B | US$131.09B | US$15.41B |
Cash flow
| Year | Operating cash flow | Free cash flow | Net income |
|---|---|---|---|
| 2025 | US$19.03B | US$17.82B | US$4.23B |
| 2024 | US$18.81B | US$17.83B | US$4.29B |
| 2023 | US$22.84B | US$22.06B | US$4.82B |
| 2022 | US$24.94B | US$24.25B | US$11.85B |
| 2021 | US$22.78B | US$21.99B | US$11.55B |
EPS forecasts
| Period | Est. EPS | Est. revenue | Analysts |
|---|---|---|---|
| 2025 | US$9.94 | US$60.97B | 15 |
| 2026 | US$14.05 | US$67.61B | 15 |
| 2027 | US$16.37 | US$73.41B | 14 |
| 2028 | US$17.92 | US$78.73B | 9 |
| 2029 | US$19.80 | US$83.28B | 3 |
| 2030 | US$20.97 | US$84.85B | 3 |
Analyst view
- Target (mean)
- US$287.08
- Target (high)
- US$315.00
- Target (low)
- US$235.00
- Strong buy
- 0
- Buy
- 31
- Hold
- 11
- Sell
- 1
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.